Related topics: Industry
DHA specialist Martek Biosciences Corporation fourth quarter results slipped three percent to $87.6 million from $90.4 in the corresponding 2008 quarter, but the company said net income rose 24 percent for the period.
"Martek's solid fiscal 2009 financial results, though impacted by the many global economic factors affecting business in general, reflect the quality of Martek's products and the desire of consumers to improve their health and well-being, even in times of economic uncertainty,” said chief executive officer, Steve Dubin.
Infant formula sales dropped five percent the company said due to de-stocking and declining US birth rates.
Copyright - Unless otherwise stated all contents of this web site are © 2000/2010 - Decision News Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department: Administration & Finance - Full details for the use of materials on this site can be found in the Terms & Conditions
